M&G PLC Acquires 110,504 Shares of Bruker Corporation $BRKR

M&G PLC grew its holdings in Bruker Corporation (NASDAQ:BRKR) by 50.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 329,234 shares of the medical research company’s stock after purchasing an additional 110,504 shares during the period. M&G PLC owned approximately 0.22% of Bruker worth $13,499,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Nisa Investment Advisors LLC lifted its position in shares of Bruker by 377.5% during the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock worth $25,000 after acquiring an additional 487 shares in the last quarter. Huntington National Bank lifted its holdings in Bruker by 750.0% during the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock worth $30,000 after purchasing an additional 645 shares in the last quarter. Allworth Financial LP boosted its stake in Bruker by 92.4% in the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock worth $30,000 after purchasing an additional 364 shares during the period. Spire Wealth Management purchased a new position in Bruker during the 2nd quarter valued at about $32,000. Finally, Caitong International Asset Management Co. Ltd increased its position in shares of Bruker by 1,354.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock valued at $33,000 after buying an additional 745 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director John A. Ornell sold 6,233 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the completion of the sale, the director owned 35,212 shares of the company’s stock, valued at $1,373,268. This trade represents a 15.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Cynthia M. Friend sold 3,535 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $32.25, for a total transaction of $114,003.75. Following the transaction, the director directly owned 18,016 shares in the company, valued at approximately $581,016. The trade was a 16.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 27.30% of the company’s stock.

Bruker Stock Up 1.8%

BRKR opened at $42.49 on Thursday. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $64.64. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The business’s 50-day moving average price is $35.59 and its 200-day moving average price is $37.14. The company has a market cap of $6.46 billion, a P/E ratio of 81.71, a P/E/G ratio of 5.31 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.12. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business had revenue of $860.50 million for the quarter, compared to analysts’ expectations of $847.40 million. During the same period in the previous year, the firm earned $0.60 EPS. The business’s quarterly revenue was down .5% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, equities analysts expect that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 2nd. Shareholders of record on Monday, December 8th will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Bruker’s dividend payout ratio is presently -125.00%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on BRKR shares. TD Cowen raised their price objective on shares of Bruker from $40.00 to $42.00 and gave the company a “hold” rating in a research report on Tuesday, November 4th. Citigroup decreased their price target on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a report on Monday, August 4th. UBS Group boosted their target price on Bruker from $40.00 to $43.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Stifel Nicolaus set a $40.00 price target on Bruker and gave the company a “hold” rating in a report on Tuesday, August 5th. Finally, Wells Fargo & Company cut their price objective on Bruker from $50.00 to $48.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Five research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $48.30.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.